CPAD's mission is to precompetitively accelerate the delivery of therapeutics for Alzheimer disease (AD) by advancing Drug Development Tools describing the foundational nature of disease progression, designing and conducting clinical trials, evaluating drug efficacy, and streamlining the regulatory review process. Members include large Pharma, patient advocacy organizations, and stakeholders from FDA, EMA, and NIH. CPAD serves the AD healthcare community as a neutral third party and focuses on key areas supporting regulatory science: Sharing of anonymized, precompetitive patient-level data from the control arms of legacy clinical trials; development of consensus data standards and novel regulatory-endorsed Drug Development Tools (e.g., prognostic imaging/fluid biomarkers, use of clinical outcome assessment instruments from wearables/remote biometric monitoring devices, quantitative drug development platforms).